

## Supplementary Files for Extracorporeal Photopheresis in Dermatological Diseases

**Supplementary Table S1.** APSA Guideline for Therapy Staging.

Category	Definition
<b>I</b>	Considered as <b>first-line</b> treatment; used as monotherapy or concomitant treatment
<b>II</b>	Considered a <b>second-line</b> treatment; used as monotherapy or concomitant treatment
<b>III</b>	Literature shows beneficial treatment but insufficient evidence. Treatment decision is based on individual scenario.
<b>IV</b>	Literature states ECP is harmful or ineffective. IRB approval is needed in order to administer treatment

**Supplementary Table S2.** APSA Guideline for Strength and Quality of Evidence.

Grading Recommendation	Quality	Implementation
<b>Grade 1A</b>	Strong recommendation with high quality evidence	Can apply to most patients without concern
<b>Grade 1B</b>	Strong recommendation with intermediate quality evidence	Can apply to most patients without concern
<b>Grade 1C</b>	Weak recommendation with high quality evidence	Strongly recommended but recommendation can change as more evidence becomes available
<b>Grade 2A</b>	Weak recommendation with high quality evidence	Application dependent on circumstance and patient's preference
<b>Grade 2B</b>	Weak recommendation with intermediate-quality evidence	Application dependent on case-by-case basis and patient's preference
<b>Grade 2C</b>	Weak recommendation with low-quality or very low-quality	Other alternatives should be considered